Sales of Animal Model Market is projected to increase at a CAGR of 5.5% through 2034

The animal model market is projected to reach a value of US$ 1.7 Billion in 2022, with an anticipated increase to US$ 2.9 Billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 5.5% from 2022 to 2032.

Animal Model Market Dynamics:

The animal model market is propelled by the expanding scope of biomedical research, where animals serve as essential tools for studying complex physiological and pathological processes. These models are instrumental in preclinical trials, toxicology studies, and understanding the efficacy of potential treatments. The rise in chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, has heightened the demand for animal models to accelerate drug discovery and development.

Additionally, the emergence of personalized medicine has spurred the utilization of genetically modified animals to mimic specific human conditions. This has led to an increased adoption of advanced animal models like genetically engineered mice, rats, and pigs. The ability to replicate human disease conditions in these models enhances the predictive value of preclinical studies, ultimately reducing the risk of failure in clinical trials.

Ethical concerns and advancements in alternative technologies, such as in vitro and in silico models, pose challenges to the animal model market. However, the complexity of biological systems and the inability of alternative methods to fully replicate in vivo conditions continue to underscore the significance of animal models in biomedical research.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=1590

Animal Model Market Future Outlook:

The future of the animal model market appears promising, with continuous innovation and technological advancements driving its evolution. Genetically modified animals, particularly mice and rats, will remain pivotal in studying specific genetic mutations and their implications for disease development. The integration of CRISPR-Cas9 technology has revolutionized the creation of precise and customized animal models, offering researchers unprecedented control over genetic modifications.

The growing trend towards translational research, aiming to bridge the gap between preclinical studies and clinical trials, will further fuel the demand for sophisticated animal models. Humanized mice, engineered to carry human tissues or cells, will play a crucial role in evaluating the safety and efficacy of novel therapeutics, particularly in the field of immunology and infectious diseases.

Advancements in imaging technologies, such as in vivo imaging and molecular imaging, will enhance researchers' ability to monitor disease progression and treatment responses in real-time within animal models. This will contribute to the development of more accurate and reliable preclinical data, optimizing the drug discovery and development process.

Market Insights:

The animal model market is witnessing a shift towards a more diverse range of species to better represent human physiology. Non-human primates, zebrafish, and dogs are gaining prominence in specific research areas. Zebrafish, for instance, are being extensively used in developmental biology and drug screening due to their transparent embryos and rapid development.

Furthermore, the market is witnessing increased collaboration between academic institutions, pharmaceutical companies, and contract research organizations (CROs). This collaborative approach aims to pool resources, expertise, and diverse perspectives to address the complexities of human diseases more effectively. The trend towards outsourcing preclinical research to specialized CROs is gaining traction, allowing pharmaceutical companies to focus on core competencies and accelerate the drug development timeline.

List of Key Companies Profiled in The Report

Genoway SA
Eurofins Scientific SE
Crown Bioscience Inc.
Envigo CRS SA
Transposagen Biopharmaceuticals, Inc.
Trans Genic Inc.
The Jackson Laboratory
Horizon Discovery Group Plc.
Charles River Laboratories International Inc.

Animal Model Market Recent Developments:

Animal model system suppliers are strategically enhancing their market presence and attracting a broader customer base through acquisitions, mergers, collaborations, and partnerships. Recent investments from major corporations have opened up international growth opportunities for the sector. Notable developments include:

Taconic Biosciences and Biomodels Collaboration (April 2022): Taconic Biosciences and Biomodels joined forces to launch the Taconic-Biomodels Microbiome Initiative (TBMI). This initiative streamlines investigators' access to comprehensive germ-free and gnotobiotic microbiome study solutions, offering a seamless approach from study design to data analysis. By combining relevant disease models, germ-free animal production, and in-vivo research design, execution, and analytics, TBMI aims to overcome long-standing hurdles in microbiome research.

Inotiv Inc. Acquires Envigo (September 2021): In a significant move, Inotiv Inc. and Envigo reached an agreement for the acquisition of Envigo by Inotiv Inc. This strategic acquisition positions both companies to enhance their access to products and services across the entire spectrum of discovery and non-clinical development, consolidating resources and expertise within a single organization.

Want Full Report? Enquire Here- https://www.factmr.com/report/1590/animal-model-market

Animal Model Market Competitive Landscape:

The animal model market is characterized by intense competition, with key players focusing on strategic collaborations, acquisitions, and product innovations to strengthen their market presence. Major companies in the market include Charles River Laboratories, The Jackson Laboratory, Envigo, Taconic Biosciences, and genOway, among others.

Strategic partnerships between pharmaceutical companies and CROs for preclinical research services are becoming increasingly common. This allows pharmaceutical companies to leverage the expertise of CROs in conducting comprehensive preclinical studies using a variety of animal models.

The animal model market is poised for continued growth, driven by the increasing complexity of biomedical research and the need for reliable preclinical data. Technological advancements, collaborations, and the diversification of animal models will be key factors shaping the market's trajectory in the coming years. As ethical considerations persist, the industry will also witness ongoing efforts to refine and reduce the use of animals in research while ensuring the highest standards of scientific rigor.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=1590

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.